Back

Comparing the anti-remodeling effect of sacubitril/valsartan and angiotensin-converting enzyme inhibition on myocardial samples of advanced heart failure patients undergoing heart transplantation

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Experiments in cardiac hypertrophy, atrophy, and remodelling Ventricular Remodelling ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor David Nagy

Semmelweis University Heart and Vascular Center, Budapest (Hungary)

6 More presentations in this session

Presentation thumbnail
Titin hyper-phosphorylation in the peripheral skeletal muscle but not the diaphragm of HFpEF: association with muscle atrophy and dysfunction.
Mrs B. Vahle (Dresden, DE)
Abstract Slides Video
Presentation thumbnail
HECT domain containing-3 (HECTD3) E3 ubiquitin ligase attenuates cardiac ischemia and hypertrophy in mice
Doctor A. Deshpande (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Relationships between 18-month kinetics and functional capacity and left ventricular remodeling and cardiac fibrosis in dilated cardiomyopathy
Doctor S. Wisniowska-Smialek (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
The transcription factor foxo3 regulates cardiac remodeling after myocardial infarction
Professor C. Skurk (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Gradual hypertensive response in aortic alterations and myocardial inflammatory activation in progressing HFpEF in mice
Mrs D. Torma (Kuopio, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Experiments in cardiac hypertrophy, atrophy, and remodelling

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The anti-remodeling effect of sacubitril/valsartan in myocardial samples of end-stage heart failure patients
thumbnail
Congress Presentation
Treatment with sacubitril/valsartan and improvement of ventricular-arterial coupling in heart failure with reduced ejection fraction
thumbnail
Congress Presentation
Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources